Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

ABSTRACT:

Purpose

To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC).

Methods

The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the literature.

Results

When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone metastases). Improved survival and QOL with moderate toxicity risk are associated with docetaxel/prednisone. For asymptomatic/minimally symptomatic men, improved survival with unclear QOL impact and low toxi

SUBMITTER: Basch E 

PROVIDER: S-EPMC4876355 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature